For example, Zheng et al. (2018) found that sGC can only improve the quality of life of HF patients, but not reduce mortality; another meta-analysis showed no benefit of vericiguat and riociguat in reducing HF-related hospitalizations or mortality; (Ullah et al., 2020) in addition, a meta-analysis by Moghaddam et al. (2021) showed that sGC stimulators can reduce the rate of HF hospitalization in heart failure with reduced ejection fraction (HFrEF), but not cardiovascular mortality, and there was no significant benefit in HFpEF. The gene discussed is SGCB; the disease is heart failure.